BioCardia, Inc. (BCDA) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 4.19M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 384.00K USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -7.39M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.19M | (m) | $384.00K | $-7.39M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $4.67M | (m) | $373.00K | $-7.82M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $4.96M | (m) | $430.00K | $-8.28M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $5.25M | (m) | $521.00K | $-8.59M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $5.24M | (m) | $621.00K | $-8.85M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $4.68M | (m) | $707.00K | $-8.45M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $4.39M | (m) | $741.00K | $-8.00M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $4.13M | (m) | $749.00K | $-7.76M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $5.07M | (m) | $823.00K | $-8.61M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $6.58M | (m) | $956.00K | $-10.41M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $7.73M | (m) | $1.03M | $-11.64M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $8.77M | (m) | $1.13M | $-12.58M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $9.04M | (m) | $1.16M | $-13.04M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $9.03M | (m) | $1.14M | $-12.08M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $8.83M | (m) | $1.18M | $-11.90M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $8.75M | (m) | $1.33M | $-12.34M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $8.85M | (m) | $1.48M | $-11.99M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $8.90M | (m) | $1.56M | $-12.98M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $8.56M | (m) | $1.66M | $-12.63M | $0.00 | (m) | (m) | (m) | Reported |
| 2021-09-30 | $8.77M | (m) | $1.86M | $-12.67M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $9.00M | (m) | $2.16M | $-13.81M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $8.86M | (m) | $2.43M | $-13.89M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $9.81M | (m) | $2.95M | $-15.53M | $3.00K | (m) | (m) | -5176.33× | Reported |
| 2020-09-30 | $9.65M | (m) | $2.91M | $-15.57M | $2.00K | (m) | (m) | -7783.00× | Reported |
| 2020-06-30 | $9.19M | (m) | $2.93M | $-14.95M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $9.18M | (m) | $2.97M | $-15.13M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $8.56M | (m) | $2.72M | $-14.21M | $112.00K | (m) | (m) | -126.90× | Reported |
| 2019-09-30 | $8.60M | (m) | $2.83M | $-14.34M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $8.85M | (m) | $2.81M | $-14.68M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $8.66M | (m) | $2.85M | $-14.17M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $8.45M | (m) | $2.77M | $-14.10M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $8.02M | (m) | $2.79M | $-13.96M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $7.46M | (m) | $2.76M | $-13.43M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $6.72M | (m) | $2.70M | $-13.15M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $5.80M | $479.00K | $2.71M | $-12.40M | $0.00 | 1210.65% | 565.14% | (m) | Reported |
| 2017-09-30 | $5.74M | $516.00K | $2.80M | $-12.35M | $109.00K | 1111.63% | 541.86% | -113.34× | Reported |
| 2017-06-30 | $4.72M | $503.00K | $2.18M | $-11.00M | $629.00K | 938.37% | 433.80% | -17.48× | Reported |
| 2017-03-31 | $3.92M | $535.00K | $1.53M | $-9.41M | $1.19M | 733.08% | 286.73% | -7.93× | Reported |
| 2016-12-31 | $3.33M | $576.00K | $942.00K | $-7.61M | $1.74M | 578.13% | 163.54% | -4.38× | Reported |
| 2016-09-30 | (m) | (m) | $9.00K | $5.37M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | $0.00 | $327.00K | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | $0.00 | $325.00K | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | $0.00 | $319.00K | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | (m) | $0.00 | $291.00K | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | $0.00 | $250.00K | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | $0.00 | $243.00K | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | $0.00 | $231.00K | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | $0.00 | $173.00K | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | $1.00K | $157.00K | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | $1.00K | $98.00K | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | $2.00K | $9.00K | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | $3.00K | $-60.00K | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | $3.00K | $-169.00K | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | $5.00K | $-307.00K | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $6.00K | $-339.00K | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | $59.00K | $11.00K | $-431.00K | (m) | (m) | 18.64% | (m) | (m) |
| 2012-06-30 | (m) | $40.00K | $19.00K | $-458.00K | (m) | (m) | 47.50% | (m) | (m) |
| 2012-03-31 | (m) | $23.00K | $28.00K | $-575.00K | (m) | (m) | 121.74% | (m) | (m) |
| 2011-12-31 | (m) | $12.00K | $37.00K | $-618.00K | (m) | (m) | 308.33% | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $0.00 | $51.00K | $-583.00K | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |